FWIW they look very good in the patients who are both high G and TN. And I would guess that the effect actually gets better in OS than in PFS, since even though they allowed xover the OS results and the PFS results were comparable. I'd guess that that is probably a significant part of the explanation as to why they chose OS as the primary endpoint in the ph iii.
The Pfs data were k nown since May. OS follows the pfs. Was there any statement that the two arms were balanced with respect to important baseline prognostics variables?
Market Data 
Markets 
AI
